SCHEDULE: Farallon Capital Management Discloses Enanta Stake

Farallon Capital Management, L.L.C. has filed a Schedule 13G, reporting beneficial ownership of 8.3% of Enanta Pharmaceuticals Inc. common stock as of June 30, 2026.

Summary

• Farallon Capital Management, L.L.C. and its associated entities have filed an amendment to their Schedule 13G, reporting their beneficial ownership of Enanta Pharmaceuticals Inc. common stock.
• As of June 30, 2026, the reporting persons collectively beneficially own 2,418,202 shares, representing 8.3% of the class of securities.
• The filing indicates that the shares are held by various Farallon Funds, for which Farallon Capital Management, L.L.C. acts as the investment manager.
• The reporting persons certify that the securities were acquired and are held in the ordinary course of business and not for the purpose of influencing control of the issuer.

Sentiment

Score: 5

Explanation: StockSavvy.ai views this filing as neutral, as it primarily reports a change in beneficial ownership without providing new financial or strategic information about the company itself.

Future Outlook

This filing does not contain forward-looking statements or guidance regarding Enanta Pharmaceuticals Inc.'s future performance.

Management Comments

• The reporting persons certify that, to the best of their knowledge and belief, the securities referred to above were acquired and are held in the ordinary course of business and were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities and were not acquired and are not held in connection with or as a participant in any transaction having that purpose or effect, other than activities solely in connection with a nomination under 240.14a-11.

Industry Context

StockSavvy.ai notes that Schedule 13G filings are routine disclosures for institutional investors crossing certain ownership thresholds. This filing indicates a significant, but not controlling, stake by Farallon Capital Management in Enanta Pharmaceuticals, a biotechnology company.

Stakeholder Impact

• Shareholders may note the increased stake by a significant institutional investor, which could be interpreted positively or negatively depending on the investor's strategy.
• The filing does not directly impact employees, customers, or suppliers as it pertains to investment ownership.

Key Dates

Keywords

beneficial ownership, Schedule 13G, investment management, shareholder, common stock, Enanta Pharmaceuticals